moncefem/clinical-trials-ai-2000-2025 huggingface dataset:
Dermoscopy Evaluation of Pigmented Skin Lesions by a Neuronal Network Clinical Decision Support: an Open Prospective Non Interventional Study
Trial ID: NCT03362138
Status: UNKNOWN
Study type: OBSERVATIONAL
Start date: 2017-12-06
Completion date: 2019-03-31
Sponsor: Assuta Hospital Systems
Conditions: Melanoma; Pigmented Skin Lesion; Dysplastic Nevi
Interventions: dermoscopy
Locations: Maccabi Healthcare Clinic
Countries: Israel
Enrollment: 80
Age range: 18 Years - 90 Years
Sex: ALL

Summary:
Malignant melanoma (MM) is a deadly cancer, claiming globally about 160000 new cases per year and 48000 deaths at a 1:28 lifetime incidence (2016).

The golden standard, dermoscopy, enables Dermatologists to diagnose with a sensitivity of 40%, and a 8-12% specificity, approximately. Additional diagnostic abilities are restricted to devices which are either unproved or experimental.

A new technology of Neuronal Network Clinical Decision Support (NNCD) was developed. It uses a dermoscopic imaging device and a camera able to capture an image. The photo is transferred to a Cloud Server and further analyzed by a trained classifier. Classifier training is aimed at a high accuracy diagnosis of Dysplastic Nevi (DN), Spitz Nevi and Malignant Melanoma detection with assistance from a Deep Neuronal Learning network (DLN). Diagnosis output is an excise or do not excise recommendation for pigmented skin lesions.

A total of 80 subjects already referred to biopsy pigmented skin lesions will be examined by dermoscopy imaging in a non interventional study. Artificial Intelligence output results, as measured by 2 different dermoscopes, to be compared to ground truth biopsies, by either classifier decisions or a novel Modified Classifier Technology output decisions.

Primary endpoints are sensitivity and specificity detection of the NNCD techniques. Secondary endpoints are the positive and negative prediction ratios of NNCD techniques.

Eligibility criteria:
Inclusion Criteria:

* Patient aged 18-90 years
* A pigmented lesion by dermoscopy.
* Clinical management by the examining dermatologist results in biopsy
* The diameter of the pigmented area is between 1 and 40 millimeters
* The patient has consented to participate in the study and has signed the Informed Consent Form

Exclusion Criteria:

* Non intact skin (ulcers, bleeding)
* The lesion is located within 1 cm of the eye
* The lesion is located on mucosal surfaces
* The lesion is on or under nails

Outcomes:
Sensitivity for Classifier results as compared to biopsy; Sensitivity for MCT results as compared to biopsy
The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometriosis Consultations
Trial ID: NCT07393568
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Start date: 2026-02-01
Completion date: 2027-01-01
Sponsor: Hadassah Medical Organization
Conditions: Endometriosis
Interventions: using Chat gpt before outpatient clinic visit
Enrollment: 94
Age range: 18 Years - None
Sex: FEMALE

Summary:
Generative artificial intelligence (AI), including large language models such as ChatGPT, Gemini, and Copilot, is increasingly used by patients to obtain medical information and prepare for clinical encounters. Although these tools often provide guideline-consistent information, their responses may be incomplete, inaccurate, or lack personalization, potentially influencing patient expectations and clinical interactions. The impact of patient AI use on satisfaction, adherence, and physician-patient communication remains poorly understood.

This prospective comparative study will evaluate the effects of patient AI use prior to gynecologic consultations for endometriosis. Women attending a specialized endometriosis clinic will be categorized as AI users or non-users based on their preparation for the visit. Patient-reported outcomes, including satisfaction, expectations, adherence to physician recommendations, and pain during physical examination, will be assessed using validated questionnaires and visual analogue scales. Physicians, blinded to AI use, will independently assess patient engagement, trust, and compliance. Visit duration will also be recorded.

The primary objective is to determine whether AI use affects patient satisfaction and adherence to treatment recommendations. Secondary objectives include evaluating physician-perceived interaction quality and concordance between AI-generated guidance and physician recommendations. Findings from this study will provide critical evidence on how AI influences patient behavior and clinical care in endometriosis, informing best practices for integrating AI-informed patients into routine clinical encounters.

Eligibility criteria:
Inclusion Criteria:

* Women aged ≥18.
* Attending clinic for endometriosis-related complaints.
* Able to give informed consent.

Exclusion Criteria:

* Cognitive impairment or psychiatric conditions that affect communication or the ability to provide informed consent

Outcomes:
Patient Satisfaction and Treatment Plan Adherence After Consultation
Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Heart Failure With Preserved Ejection Fraction (HFpEF).
Trial ID: NCT04603404
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2019-01-01
Completion date: 2030-12
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions: Heart Failure, Diastolic
Locations: Fuwai Hospital
Countries: China
Enrollment: 430
Age range: None - None
Sex: ALL

Summary:
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.

Eligibility criteria:
Inclusion Criteria:

* left ventricular ejection fraction (LVEF)≥50%；
* N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml;
* symptoms and syndromes of heart failure;
* At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).

Exclusion Criteria:

* Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.
* Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;
* Severe arrhythmia;
* Severe primary cardiac valvular disease;
* Restrictive pericardial disease;
* Refuse to participate in the study.

Outcomes:
All-cause Death; Cardiovascular Death; Hospitalization Due to Heart Failure
Construction of Nutritional Optimization Path for Prevention and Treatment of Common Mental Diseases Based on Skin Response Quantification Instrument
Trial ID: NCT04504058
Status: UNKNOWN
Study type: OBSERVATIONAL
Start date: 2020-10-01
Completion date: 2021-10-01
Sponsor: Shanghai Mental Health Center
Conditions: Clinical High-risk
Interventions: routine clinical treatment
Locations: Shanghai Mental Health Center
Countries: China
Enrollment: 100
Age range: 14 Years - 45 Years
Sex: ALL

Summary:
The project will focus on the major technical difficulty of "lack of effective nutritional intervention measures for early risk of common mental diseases in China", and rely on the platform of psychiatric risk identification and treatment specialty of Shanghai Mental Health Center, an authoritative institution in the field of mental health, and focus on the effective application of the domestic independent research and development of the artificial intelligence nicotinic acid skin flushing reaction quantification instrument.

Eligibility criteria:
Inclusion Criteria:

* be aged 14 to 45-year-old；
* have had at least 6-years of primary education；
* be drug-naïve；
* be understanding the survey, be willing to enrol in the study and sign the informed consent；
* Through the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS), the participants should meet the Criteria of Prodromal Syndrome. Participants should fulfil at least one of the prodromal syndrome criteria: (1) brief intermittent psychotic syndrome, (2) attenuated positive symptom syndrome, or (3) genetic risk and deterioration syndrome.

Exclusion Criteria:

* Through the Mini-International Neuropsychiatric Interview (MINI), Axis I mental disorders such as schizophrenia, affective disorders, and anxiety spectrum disorders will be excluded;
* Acute or chronic renal failure; liver cirrhosis or active liver diseases;
* Abnormal laboratory tests results judged by the researchers to be clinically significant and considered to affect the efficacy of the test drugs or the safety of the subjects;
* Severe or unstable physical diseases, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension (including untreated or uncontrolled hypertension), malignant tumours, immune compromise, and blood glucose above 12 mmol/L;
* Alcohol abuse within 30 days, or alcohol or drug dependence within 6 months before the trial;
* Pregnant or lactating women, or women in childbearing age who are positive in urine human chorionic gonadotropin test, or men and women who do not take effective contraceptive measures or plan for pregnancy within 3 months after the initiation of the trial;
* Stroke within the last month;
* Participating in any clinical trial within 30 days before the baseline;
* Other situations judged by the investigators not to be suitable for the clinical trial.

Outcomes:
Conversion to psychosis; Poor function
Multiple Digital Biomarkers for Optimization of IBD Care
Trial ID: NCT07159776
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Start date: 2025-09-08
Completion date: 2026-12-31
Sponsor: Imelda GI Clinical Research Center
Collaborators: Agentschap Innoveren & Ondernemen (VLAIO)
Conditions: Crohn Disease (CD); Ulcerative Colitis (UC); Inflammatory Bowel Disease (IBD)
Interventions: monitoring of wearable data, shopping data, biomarkers and patient reported outcomes
Locations: Imelda General Hospital
Countries: Belgium
Enrollment: 80
Age range: 18 Years - None
Sex: ALL

Summary:
To develop digital biomarkers associated with disease activity of inflammatory bowel disease

Eligibility criteria:
Inclusion Criteria:

* Males or females aged \> 18 years
* Diagnosis of CD, UC or IBD-unspecified for at least 1 month
* Treatment with conventional or advanced therapy for IBD at initiation of the study
* The patient must have access to an email address
* The patient must be willing to perform all the groceries shopping at any of the Colruyt Group stores during this study, using an Xtra card created by the study team.
* Capacity to independently answer regular digital questionnaires
* Capacity and willingness to use a smartphone and activity tracker

Exclusion Criteria:

* Planned extended (\> 1 month) overseas travel during the study period of 12 months, if internet access would be impossible, inconvenient or unaffordable during this time
* Previous colectomy
* Inability to communicate well with investigators or unable to comply with the study requirements
* Significant medical condition interfering with physiological measurements trough a wearable device (heart failure, pacemaker or defibrillator)
* Inclusion or planned inclusion in an interventional IBD-related clinical trial

Outcomes:
Proportion of patients in which a flare can be detected based on passive monitoring data.
Evaluation of the Effects of Traditional and E-Learning Methods in Cancer Pain Care Education on Learning Outcomes and Institutional Costs
Trial ID: NCT07461974
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2026-06-01
Completion date: 2026-12-31
Sponsor: Bilecik Seyh Edebali Universitesi
Collaborators: Eskisehir Osmangazi University
Conditions: Cancer Pain; Nursing Students; Nursing Education
Interventions: e-learning; traditional group
Enrollment: 100
Age range: 18 Years - None
Sex: ALL

Summary:
Cancer pain is a significant clinical problem that directly affects patients' quality of life and requires nurses to be equipped with adequate knowledge and skills to provide effective care. The current shift in knowledge and skill acquisition from traditional teaching methods toward e-learning-based approaches has increased the importance of comparing the effects of these educational methods on learning outcomes in cancer pain management education.

Within this context, the course content on cancer pain management will be developed using both traditional and e-learning methods based on the ADDIE instructional design model. The effects of these two methods on students' learning outcomes and institutional teaching costs will be evaluated. Thus, this study aims to contribute to identifying effective and cost-efficient teaching strategies in nursing education.

Eligibility criteria:
Inclusion Criteria:

* Students who have access to the internet and a computer/mobile phone,
* Students who have successfully completed the Fundamentals of Nursing course,
* Students who are taking the Internal Medicine Nursing course for the first time,
* Students who voluntarily agree to participate in the study.

Exclusion Criteria:

* Students who are repeating the Internal Medicine Nursing course,
* Students who have taken the Palliative Care and Nursing or Oncology Nursing courses,
* Students who have been diagnosed with cancer themselves or have a relative diagnosed with cancer,
* Students who were admitted to the nursing department through the Vertical Transfer Exam (DGS) after graduating from an associate degree program in a health-related field,
* Students who graduated from a Vocational Health High School,
* Students who were admitted through the International Student Examination.

Outcomes:
Cancer Pain Knowledge Test; Scenario-Based Assessment of Practical Skills Form; Motivation Scale Regarding Instructional Material; Institutional Cost Information Form; Visual Analog Scale
Artificial Intelligence Training Program Versus Standard Correction for Forward Head and Rounded Shoulder in Non-specific Neck Pain
Trial ID: NCT07236385
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2025-11-30
Completion date: 2026-10-01
Sponsor: Cairo University
Conditions: Forward Head Posture; Rounded Shoulder Posture; Upper Cross Syndrome
Interventions: AI based exercise; standard corrective exercises
Locations: Faculty of Physical Therapy
Countries: Egypt
Enrollment: 46
Age range: 18 Years - 35 Years
Sex: ALL

Summary:
this study will be to evaluate the effectiveness of AI-recommended exercise interventions versus standard corrective exercises in management of non-specific neck pain with forward head and rounded shoulder posture. with the goal of improving neck pain, functional disability, forward head, and rounded shoulder postures.

Eligibility criteria:
Inclusion Criteria: Subjects with non-specific neck pain who had localized neck pain felt it anywhere along the cervical spine, from the superior nuchal line to the first thoracic spinous process.

Neck pain between 3 and 8cm on a visual analogue scale. Subjects suffering from chronic (\> 12 weeks) neck pain. Subjects with forward head posture with craniovertebral angle (CVA) angle less than 50 degrees.

Subjects with rounded shoulder posture as shoulder angle \< 52. Subjects must not have received any pharmacological medication related to their musculoskeletal condition as non-steroidal anti-inflammatory drugs or muscle relaxant for at least three months prior to enrolment in the study.

Subjects must not have involved in any form of physical therapy or structured postural correction programs within the 6 months prior to study -

Exclusion Criteria:

1. Musculoskeletal diseases, cardiopulmonary diseases, and a history of surgery that could affect the experiment.
2. History of cervical spine injury or surgery.
3. Neck pain secondary to other conditions (e.g. Neoplasm, neurological diseases or vascular diseases).
4. Spondylosis and spondylolisthesis
5. A neurological disease, infection.
6. Inflammatory arthritis in the cervical spine.
7. Poor general health status that would interfere with the exercises -

Outcomes:
The craniovertebral angle; Shoulder angle; functional disability; pain level
Sarcopenia in Cirrhosis and Chronic Inflammatory Bowel Disease: An Austrian Biobanking Study
Trial ID: NCT06632743
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2023-02-01
Completion date: 2035-12
Sponsor: Medical University of Graz
Conditions: Sarcopenia
Locations: Medical University of Graz
Countries: Austria
Enrollment: 1000
Age range: 18 Years - None
Sex: ALL

Summary:
The investigators aim to set up a biobanking study in Graz, Austria, to study sarcopenia in liver cirrhosis and chronic inflammatory bowel disease by collecting a standardized dataset including routine clinical and biochemical tests; biosamples to assess novel biomarker as well as advanced clinical assessments. In a small country like Austria, a nationwide biobanking study can enhance research enormously. The investigators therefore aim to extend the registry to all tertiary liver care centers in Austria in a second step.

Eligibility criteria:
Inclusion Criteria:

* Age \>18y
* Informed consent
* CT/MRI scan as part of routine care within +/-2 month of the study visit

Exclusion Criteria:

* Hepatic encephalopathy \> grade 2 and or other cognitive disorder not allowing informed consent
* Hepatocellular carcinoma stage BCLC C or D
* Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol

Outcomes:
Austrian-wide sarcopenia register
Prospective Study of Preoperative Diagnostic Endoscopy for the Diagnosis of Occult Metastatic Lesions of Operable Pancreatic Cancer
Trial ID: NCT04899739
Status: COMPLETED
Study type: INTERVENTIONAL
Phase: NA
Start date: 2021-12-05
Completion date: 2025-11-12
Sponsor: IHU Strasbourg
Conditions: Pancreatic Cancer
Interventions: Echoendoscopy
Locations: Service de Chirurgie Digestive et Endocrinienne
Countries: France
Enrollment: 33
Age range: 18 Years - 95 Years
Sex: ALL

Summary:
Nowadays pancreatic cancer is one of the deadliest oncological pathologies. The only effective curative tool is the surgery. Before the intervention, an endoscopic ultrasound is performed on the patient to carry out the biopsy of the main tumor. In this study, the echoendoscopie will be extended to lymph node staging away from the surgical field in order to implement a simple classification of lymph nodes, based on non-invasive ultrasound criteria. This would facilitate the location and qualification of peripancreatic lymph nodes and distant from the tumor, and therefore the staging of the tumor.

Eligibility criteria:
Inclusion Criteria:

1. Patient over 18 years old
2. Patient with a solid or degenerated cystic tumor of the pancreas requiring curative surgery
3. Patient with a complete clinical examination performed
4. Patient with no contraindication to anesthesia, upper digestive endoscopy and pancreatic surgery
5. Patient able to receive and understand information relating to the study and give informed written consent
6. Patient affiliated to the French social security system

Exclusion Criteria:

1. Patient presenting with bleeding disease with disorder hemostasis and coagulation (PT \<60%, TCA\> 40 s and platelets \<60,000 / mm3)
2. Patient on anticoagulant or antiaggregant treatment that cannot be temporarily interrupted
3. Patient carrying a right-left shunt, a severe pulmonary arterial hypertension (high blood pressure pulmonary\> 90 mm Hg), uncontrolled systemic hypertension or suffering from respiratory distress syndrome.
4. Pregnant or breastfeeding patient
5. Patient in exclusion period (determined by a previous study or in progress)
6. Patient under legal protection
7. Patient under guardianship or trusteeship

Outcomes:
Rate of lymph nodes correctly categorised by ultrasound endoscopy. (Sensitivity); Rate of lymph nodes wrongly categorised by ultrasound endoscopy. (Specificity)
Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE): a Retrospective Monocentric Pilot Study on Big-data
Trial ID: NCT07037719
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2025-01-17
Completion date: 2026-01-17
Sponsor: Centre Hospitalier Universitaire, Amiens
Conditions: Emergency Department Visit
Locations: CHU Amiens-Picardie
Countries: France
Enrollment: 300000
Age range: 18 Years - None
Sex: ALL

Summary:
The augmented rehabilitation of emergency surgeries (ARES, RAUC in French) is a research program supported by Amiens-Picardy University Hospital and the University of Picardy Jules Verne. The RAUC program aims to enhance by multiple levers (enhanced recovery programs, artificial intelligence, organizational optimization, connected devices) the management of patients operated for digestive emergency surgery. RAUCisable aims to optimize the inclusion of eligible patients in the RAUC-AMIENS study and improve predictive models for patient management.

Eligibility criteria:
Inclusion Criteria:

* Adults (age 17+), all ED patients

Exclusion Criteria:

* Patients who object to data use

Outcomes:
Area Under the ROC Curve
Continuous Cough Monitoring for Early Detection of COPD Exacerbations Using Hyfe
Trial ID: NCT07212439
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2025-10-29
Completion date: 2026-09
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Collaborators: Hyfe Inc
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Locations: Clinica San Miguel; Clínica Universidad de Navarra, Universidad de Navarra; Servicio Navarro de Salud
Countries: Spain; Spain; Spain
Enrollment: 50
Age range: 18 Years - None
Sex: ALL

Summary:
This study is for adults with COPD. Flare-ups of COPD, also known as exacerbations, can be serious and lead to hospital stays. The purpose of this research is to see if continuously and automatically monitoring a person's coughs can help predict these flare-ups early, before they become severe. Participants will use the Hyfe cough monitoring system, which includes a watch-like device worn on the wrist and a smartphone application. The system privately counts the number of coughs without recording any audio. Participants will also answer a short, weekly questionnaire about their COPD symptoms. This is an observational study, which means it will not change the regular medical care a participant receives. The participants and their care providers will not see the cough counts. The doctor will continue to manage their COPD as usual.

Eligibility criteria:
Inclusion criteria:

* Must be 18 years of age or older.
* Must have an existing diagnosis of COPD.
* For the inpatient cohort, participants must be currently assessed as having a moderate/severe exacerbation.
* For the outpatient cohort, participants must have had at least one exacerbation of any severity in the last 12 months.
* For the outpatient cohort, at least one month must have passed since the last exacerbation.

Exclusion criteria:

* Individuals who are unable to provide informed consent.
* Individuals who are unable to adhere to study procedures.
* For the inpatient cohort, individuals requiring invasive or non-invasive ventilation.
* Individuals who live with a person who has a chronic cough.

Outcomes:
Predictive accuracy of Hyfe cough monitoring for COPD exacerbations